Open-label, Non-randomized, Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 140 MBq (ca. 5 mSv) ZK 6032924 (BAY85-8101) for Its Diagnostic Potential in Either Drug-naïve or Specifically (IFN-beta) Pretreated Patients With Multiple Sclerosis (MS) With Acute Relapse or Patients With Clinically Isolated Syndrome (CIS), Compared to Healthy Volunteers
Latest Information Update: 06 Nov 2021
At a glance
- Drugs BAY 858101 (Primary)
- Indications Multiple sclerosis
- Focus Diagnostic use
- Sponsors Bayer
- 02 May 2014 New trial record